Clinical Trial Update: BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I [Phase 1]

View source ↗

Summary

Phase I study in Japan evaluating the combination of BIBF 1120 (nintedanib) with docetaxel in patients with advanced non-small-cell lung cancer completed, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BIBF 1120 (nintedanib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1 | Status: COMPLETED | Results posted: 2014-12-04